Skip to Content

Tengion Inc TNGNQ Stock Quote

| Rating as of

Morningstar‘s Stock Analysis TNGNQ

There is no Morningstar’s Analysis data available.

Key Statistics TNGNQ

Company Profile TNGNQ

Business Description

Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.

3929 Westpoint Boulevard, Suite G
Winston-Salem, NC, 27103
T +1 336 722-5855
Industry Biotechnology
Most Recent Earnings Sep 30, 2014
Fiscal Year End Dec 31, 2014
Stock Type Distressed
Employees 27